U.S. market Closed. Opens in 12 hours 5 minutes

ACHL | Achilles Therapeutics plc Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue4.73M3.69M3.29M778.00K303.25K
Gross Profit-4.73M-3.69M-3.29M-778.00K-303.25K
Operating Expenses80.25M78.38M64.19M33.73M13.78M
Selling, General & Admin12.34M21.12M21.97M11.10M4.70M
Research & Development67.91M57.26M42.22M22.63M9.07M
Other Operating ExpensesN/A7.32M3.13M531.00K-215.00K
Operating Income-84.98M-78.38M-64.19M-33.73M-13.78M
Other Expenses / Income6.10M7.32M3.13M531.00K-215.00K
Before Tax Income-78.88M-71.06M-61.06M-33.20M-13.99M
Income Tax Expenses-8.94M111.00K37.00K3.00K130.14K
Net Income-69.94M-71.18M-61.10M-33.20M-13.99M
Interest ExpensesN/A-7.32MN/AN/AN/A
Basic Shares Outstanding39.97M39.14M28.65M40.62M1.64M
Diluted Shares Outstanding39.97M39.14M28.65M40.62M1.64M
EBITDA-80.25M-74.69M-60.91M-32.95M-13.47M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-78.88M-78.38M-61.06M-33.20M-13.86M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙